RxDoctor Payments Data

Matthew Smeds, MD

Vascular Surgery · Saint Louis, MONPI 1003067240

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $12,176 of the $13,547 with a category attached, or 89.9%. It is spread thinly across 28 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $3,158 and has fallen 64.5% since, to $1,122 in 2025.

$13,547in general payments, 2019–2025

Across 165 payments — averaging $82.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Silk Road Medical, Inc.$3K
  • W. L. Gore & Associates, Inc.$3K
  • Penumbra, Inc.$2K
  • Medtronic$1K
  • Bolton Medical Inc$973
  • Getinge USA Sales, LLC$763
  • plus $4K from 22 others
$24,950in research payments, 2019–2025

Across 12 payments — averaging $2079.17 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Bard Peripheral Vascular, Inc.$14K
  • Merit Medical Systems Inc$4K
  • Bolton Medical Inc$4K
  • W. L. Gore & Associates, Inc.$2K

What the payments were for

  • Travel & lodging$1,1398%
  • Food & beverage$12,17690%
  • Entertainment$2322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,547 in reported general payments places this provider in the 70th percentile of 92 vascular surgery providers in Missouri.

See all vascular surgery providers in Missouri

Medicare billing

Part B allowed, 2024
$73,681
Medicare patients
310
Services billed
562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban11$10,564
Cilostazol35$1,009
Gabapentin26$213
ClopidogrelClopidogrel Bisulfate16$74

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$88$10,56411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 92 vascular surgery providers in Missouri.

Other vascular surgery in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →